논문 및 학회자료

Preclinical characterization of FM101, a first-in-class A3 adenosine receptor modulator for the treatment of non-alcoholic steatohepatitis. European Association of the Study of Liver (EASL 2021)

Admin │ 2022-02-13

HIT

513



이전글 Safety Evaluation of FM101, an A3 Adenosine Receptor Modulator, in Rat, for Deve...
다음글 Population pharmacokinetics of FM101 in healthy volunteers and long-term safety ...